AT-109 / AbClon - LARVOL DELTA

AbClon, CB·CPS issuance of 31 billion decided.. Daily Partners Lead [Google translation] (Biospectator) - "AbClon held a board meeting on the 28th and announced that it decided to raise 31 billion won through a paid-in capital increase by issuing convertible bonds (CB) and third-party allocated convertible preferred shares (CPS)...AppClon explained that this funding acquisition will allow it to focus on clinical trials and R&D while improving its financial soundness. In particular, it emphasized that it will focus on completing Phase 2 clinical trials for the successful commercialization of its core AT101 and meeting market and investor expectations through the successful development of its core pipeline....AppClon plans to use this fund to focus on completing and commercializing phase 2 clinical trials of its CD19 CAR-T 'AT101' for blood cancer and developing the next-generation solid cancer HER2 switchable CAR-T 'AT501'. It also plans to strategically use it to develop T cell engager EGFRx4-1BB dual antibodies 'AM105 (colon cancer)' and 'AT109 (prostate cancer)'."

Financing • Colon Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor